CURRICULUM VITAE Part I General Information DATE PREPARED ...

which then give rise to secretory cells and thus represent progenitor/stem cells. In contrast, my
analysis of the urothelium shows that umbrella (superficial) cells can develop and be maintained
independently from p63-positive cells. I am currently utilizing animal models to further
characterize the role of p63 in the development and renewal of the prostate and bladder
epithelium. This approach is likely to offer new insights in the biology of prostate and bladder
development and open new perspectives in the identification of the cell of origin of prostate and
bladder carcinoma.
An important focus of my research in kidney cancer is the identification of novel oncogenes and
tumor suppressor genes. In collaboration with Drs. Kaelin and Beroukhim at DFCI and the
Broad Institute, we are currently using an integrated analysis of single-nucleotide polymorphism
(SNP) arrays data with matched gene expression data to identify genes targeted by non-random
genetic aberrations in RCC. Results from these studies have the potential to identify new drug
targets and may eventually lead to new therapeutic approaches for patients with kidney cancer.
My laboratory is also very involved in translational research activities. I currently serve as the
Director of the Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core of the DF/HCC
Kidney Cancer SPORE and Program. I am also the Director of the DF/HCC Tissue Microaaray
and Imaging Core.
Teaching contributions: I have been actively involved in teaching since the beginning of my
career. I daily teach and tutor post-doctoral fellows and research assistant working in my
research laboratory. Moreover, I serve as a Tutor in the Pathology course at Harvard Medical
School.
Clinical contributions: Throughout my career I have been involved in both patient care and in
the development of new tools that could be helpful in the diagnosis and treatment of diseases.
As a Research Fellow, I developed a novel PCR-based T-cell clonality assay, which is currently
being utilized for the diagnosis of T-cell lymphomas (Signoretti et al., Am J Pathol, 1999 and
accompanying editorial). More recently, I demonstrated that p63 is a reliable marker of prostate
basal cells that is not expressed in prostate carcinoma. After extensive validation by other
groups, p63 immunohistochemistry is currently used in routine clinical practice for the
evaluation of challenging prostate biopsies.
B. Funded Research Support:
Past
1996-1997 Oncor, Inc. Evaluation of the Oncor HER-2/neu (ERBB2) gene
amplification detection kit for the interpahse detection of HER-2/neu
(ERBB2) genomic sequences in human breast tissue for node-negative
primary breast cancer. Multi-institutional study for FDA approval of
the HER-2/neu (ERBB2) gene amplification detection kit. (Kit FDA
approved Jan 1998). Co-investigator.
1997-1998 Ministero della Pubblica Istruzione, Rome, Italy. Detection of B-cell
clonality in cutaneous B-cell infiltrates. Co-investigator.
2001 Hershey Foundation Award (Signoretti, DFCI). A mouse model for
prostate stem cells. Principal Investigator.
2001-2004 DOD U.S. Army, CDMRP - New Investigator Award (Signoretti,
DFCI). The basal cell marker p63 and prostate stem cells. Principal
Investigator.
4